Allworth Financial’s BioXcel Therapeutics BTAI Stock Holding History

Allworth Financial’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13	Closed	-$10K	–	1487
2020 Q4	$10K	Buy	+13	New	+$10.1K	﹤0.01%	831

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allworth Financial's BTAI Position: Q1 2021 in Review

Allworth Financial sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 13 shares — an estimated $10K sold.

Allworth Financial first reported a position in BTAI in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

Allworth Financial reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
Allworth Financial sold 13 BioXcel Therapeutics shares in Q1 2021, an estimated $10K.
Allworth Financial first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 1 quarter.
Allworth Financial's BioXcel Therapeutics position peaked at $10K in Q4 2020.
116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on Allworth Financial's 13F filing for Q1 2021, filed 29 Apr 2021.